Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities

Jeong, Sehan; Afroz, Sharmin; Kang, Donghyun; Noh, Jeonghwan; Suh, Jooyeon; Kim, June Hyuk; You, Hye Jin; Kang, Hyun Guy; Kim, Yi-Jun; Kim, Jin-Hong

doi:10.14348/molcells.2023.0079

Cited by 2 publications

(1 citation statement)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although Immunotherapy has revolutionized cancer treatment, immuno‐oncology agents have not yet been approved for patients with sarcomas attributed to the limitations of low tumor mutation burden and the immunosuppressive TME [ 115 ]. However, several research have indicated that immunotherapy may represent an efficient therapeutic strategy for this group of diseases, including cancer vaccines, immune checkpoint blockade and adoptive cell transfer [ 116 ]. Future studies investigating novel immunotherapy strategies in rare cancer types like sarcomas should incorporate the analysis and intervention of commensal bacteria, which will allow for a better understanding of the gut microbiota involved in sensitivity and treatment resistance to immune‐oncology agents.…”

Section: Discussionmentioning

confidence: 99%

Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies

Xie,

Liu,

Deng

et al. 2024

iMeta

View full text Add to dashboard Cite

Gut microbiota is essential for maintaining local and systemic immune homeostasis in the presence of bacterial challenges. It has been demonstrated that microbiota play contrasting roles in cancer development as well as anticancer immunity. Cancer immunotherapy, a novel anticancer therapy that relies on the stimulation of host immunity, has suffered from a low responding rate and incidence of severe immune‐related adverse events (irAEs). Previous studies have demonstrated that the diversity and composition of gut microbiota were associated with the heterogeneity of therapeutic effects. Therefore, alteration in microbiota taxa can lead to improved clinical outcomes in immunotherapy. In this review, we determine whether microbiota composition or microbiota‐derived metabolites are linked to responses to immunotherapy and irAEs. Moreover, we discuss various approaches to improve immunotherapy efficacy or reduce toxicities by modulating microbiota composition.

show abstract

Section: Discussionmentioning

confidence: 99%

Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies

Xie,

Liu,

Deng

et al. 2024

iMeta

View full text Add to dashboard Cite

show abstract

Evaluation of tumorous LCP1 and ADPGK as predictive biomarker for immune-related adverse events in bone and soft tissue sarcomas treated with anti-PD-1 and anti-PD-L1 antibodies

Zhang,

Wang,

Zeng

et al. 2024

Preprint

View full text Add to dashboard Cite

Immune checkpoint inhibitor (ICI) have been utilized in bone and soft tissues sarcoma patients under multiple circumstances in combination with surgeries and chemotherapy. Regretfully, immune-related adverse events (irAE) increases as the usage of ICI increases. Since a large portion of bone and soft tissues sarcoma patients gain long survival times after successful removal of the tumors which makes clinicians to avoid regimens that causes adverse events, especially lifetime irAE. Hence, predicting the development of irAE are of special significance for utilizing ICI in bone and soft tissues sarcoma patients. We have retrospectively stained tumorous LCP1 and ADPGK, two biomarkers previously reported to predict ICI induced irAE, with surgical removed, formalin-fixed and parrffin-embedded samples in a cohort of 56 bone and soft tissues sarcoma patients. We observed that the most common irAE in bone and soft tissues sarcoma patients received ICI is hyperglycemia and high grade irAE happens predominately in patients over 30 years old. Immunochemistry revealed that both LCP1 and ADPGK were elevated in tumorous tissues of patients developed irAE and bivariate-model of LCP1 and ADPGK severs as a better biomarker in comparison to LCP1 or ADPGK alone in the entire cohort. In osteosarcoma, LCP1 alone exhibited an outstanding predication value with an AUC of 0.9244 (P value of 0.0013 and a 95% CI of 0.8178 to 1.000). LCP1 and ADPGK bivariate-model serves as a promising biomarker for predicting ICI induced irAE in bone and soft tissues sarcoma patients while LCP1 alone works better in bone malignancy especially in osteosarcoma.

show abstract

Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities

Cited by 2 publications

References 119 publications

Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies

Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies

Evaluation of tumorous LCP1 and ADPGK as predictive biomarker for immune-related adverse events in bone and soft tissue sarcomas treated with anti-PD-1 and anti-PD-L1 antibodies

Contact Info

Product

Resources

About